Medication info
Avaltan Tablet 10/160 mg

Avaltan Tablet 10/160 mg

Prescription medicationTabletOral
Ingredient · strength
Valsartan›160mg / 1 tabletAmlodipine Besylate›13.87mg / 1 tablet
Manufacturer / importer
Donggu Bio Pharmaceutical Co., Ltd.
Appearance
Bright yellow oval film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201402898 · Approved 2014.06.30 · Insurance code 657306470

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
The recommended dose of this medicine is 1 tablet once daily, taken with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). It is recommended that the dose be adjusted using the individual components (amlodipine or valsartan) before starting this medicine; however, a direct switch to this medicine may be considered if blood pressure is not adequately controlled with monotherapy using the individual components, as follows. ㆍ5/80 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 80 milligrams as monotherapy. ㆍ5/160 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 160 milligrams as monotherapy. ㆍ10/160 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams or valsartan 160 milligrams as monotherapy, or with 5/160 milligrams. Patients taking valsartan and amlodipine concomitantly may switch to this medicine (a fixed-dose combination with the same amounts of each active ingredient) for convenience. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or greater); however, this medicine should not be administered to patients with severe renal impairment (creatinine clearance less than 10mL/min) or patients on dialysis. In patients with moderate renal impairment, monitoring of potassium levels and creatinine is recommended. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. Do not administer this medicine to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. Elderly patients aged 65 years or older: Use caution when increasing the dose.
Child dose
Pediatric patients under 18 years: Use of this medicine is not recommended because safety and efficacy have not been established.

Ingredients

Manufacturer
Donggu Bio Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication is used to effectively lower blood pressure in patients with essential hypertension whose blood pressure is not sufficiently controlled by monotherapy with amlodipine or valsartan.

How to take

Adult dose

The recommended dose of this medicine is 1 tablet once daily, taken with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). It is recommended that the dose be adjusted using the individual components (amlodipine or valsartan) before starting this medicine; however, a direct switch to this medicine may be considered if blood pressure is not adequately controlled with monotherapy using the individual components, as follows. ㆍ5/80 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 80 milligrams as monotherapy. ㆍ5/160 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 160 milligrams as monotherapy. ㆍ10/160 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams or valsartan 160 milligrams as monotherapy, or with 5/160 milligrams. Patients taking valsartan and amlodipine concomitantly may switch to this medicine (a fixed-dose combination with the same amounts of each active ingredient) for convenience. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or greater); however, this medicine should not be administered to patients with severe renal impairment (creatinine clearance less than 10mL/min) or patients on dialysis. In patients with moderate renal impairment, monitoring of potassium levels and creatinine is recommended. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. Do not administer this medicine to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. Elderly patients aged 65 years or older: Use caution when increasing the dose.

Child dose

Pediatric patients under 18 years: Use of this medicine is not recommended because safety and efficacy have not been established.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during pregnancy, especially during the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. This medication should not be used in patients who are allergic to the active ingredients or similar class drugs, in women who are pregnant or may become pregnant, in nursing women, or in patients with severe kidney or liver impairment. Patients with fluid or sodium depletion may experience low blood pressure, so it is essential to check their status before taking the medication and to closely monitor blood pressure and status during treatment. Patients with high potassium levels or those taking other medications that may increase potassium should frequently monitor their potassium levels and use the medication cautiously. The use of this medication may not be safe in patients with vascular kidney issues or those who have recently undergone kidney transplantation and should be carefully considered. If symptoms of angioedema occur, the medication should be discontinued immediately and not resumed, and patients with heart failure or after a myocardial infarction should also frequently check kidney function.

Side effects

nasopharyngitis, influenza, hypersensitivity, visual impairment, anxiety, headache, dizziness, drowsiness, orthostatic dizziness, paresthesia, vertigo, tinnitus, tachycardia, palpitations, syncope, orthostatic hypotension, hypotension, cough, pharyngeal and laryngeal pain, diarrhea, nausea, abdominal pain, constipation, thirst, rash, erythema, hyperhidrosis, rash, itching, joint swelling, back pain, arthritis, muscle spasm, lethargy, polyuria, nocturia, erectile dysfunction, edema, angioedema, facial edema, peripheral edema, fatigue, flushing, weakness, facial flushing, decreased hemoglobin, decreased hematocrit, neutropenia, thrombocytopenia, hypersensitivity including serum sickness, elevated serum potassium, vasculitis, elevated liver function test levels, angioedema, vesicular dermatitis, myalgia, renal failure, kidney injury, elevated serum creatinine, insomnia, decreased libido, pharyngitis, rhinitis, sinusitis, upper respiratory infection, viral infection, intestinal vascular edema, diplopia, thrombocytopenia, leukopenia, allergic reaction, hyperglycemia, insomnia, mood changes, tremor, sensory impairment, taste disturbance, peripheral neuropathy, hypertonicity, arrhythmia, bradycardia, atrial fibrillation, ventricular tachycardia, myocardial infarction, vasculitis, dyspnea, rhinitis, vomiting, dyspepsia, pancreatitis, gastritis, gingival hyperplasia, hepatitis, jaundice, alopecia, purpura, skin depigmentation, photosensitivity reaction, angioedema, urticaria, erythema multiforme, Stevens-Johnson syndrome, myalgia, urinary disorders, nocturnal enuresis, gynecomastia, pain, malaise, chest pain, weight loss, weight gain, elevated liver enzymes, chest discomfort, abdominal discomfort, gastroesophageal reflux disease, neck pain, hypercholesterolemia, hypoglycemia, neuroexcitation, sensory impairment, Stevens-Johnson syndrome

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. The appropriate storage temperature is room temperature between 1 and 30 degrees Celsius. Storing it this way will help maintain the drug's effectiveness for a longer period.

Appearance and packaging

Appearance

Bright yellow oval film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.